‘Just ten antibiotic classes are being used to treat 86% of all bacterial infections’.
But while these statistics are alarming, global strategies to tackle antibiotic resistance are advancing too, providing opportunities to slow the advance of this threat. The last few years have seen a significant jump in the number of new pipeline antibiotics and targeting strategies, as well as improvements in and increasing use of diagnostics methods, alongside more informed drug prescribing practices, integrated approaches and the use of surveillance data on local infections, all of which offer opportunities to slow the advance of antibiotic resistance.
These are some of the conclusion from a new report on antibiotic resistance, involving the participation of 650 clinicians and researchers in 80 countries. The findings of this study provide a comprehensive overview of current and evolving practices, developments and strategies and their importance to the better management of antibiotic resistance.
1. The top three therapeutic areas:
relating to participants work with antibiotics or antibiotic resistance (e.g. general bacterial infections, infections associated with autoimmune disease etc). Options: arthritis, autoimmune diseases, general bacterial infections, bone metabolism, cancer, cardiovascular, central nervous system, dermatology, endocrine, gastrointestinal, genitourinary system, haematology, inflammation, metabolic disorders, musculoskeletal disorders, nutrition, obstetrics and gynaecology, ophthalmology, pain, respiratory, viral infections or other.
2. Top three infection types (e.g. lower respiratory tract, urethritis etc):
with which clinicians and other participants work.
3. Bacterial and viral infections:
Participant’s current use of labor
Copyright©2012 Vocus, Inc.
All rights reserved